araag2/HINT huggingface dataset:
Clinical trial NCT00193180 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: imatinib, docetaxel
SMILES: CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

        To be included in this study, you must meet the following criteria:

          -  Metastatic breast cancer confirmed by biopsy

          -  No more than one prior chemotherapy regimen for metastatic breast cancer

          -  Able to perform activities of daily living with minimal assistance

          -  Adequate bone marrow, liver and kidney function

          -  Age 18 years or older

          -  Give written informed consent

        Exclusion Criteria:

        You cannot participate in this study if any of the following apply to you:

          -  Moderate to severe peripheral neuropathy

          -  Uncontrolled blood pressure or uncontrolled heart beat irregularities

          -  Diabetes Mellitus with fasting blood sugar greater than 200 mg %

          -  Significant heart disease within the prior 6 months

          -  Severe or uncontrolled medical disease

          -  Active uncontrolled infection

          -  Known chronic liver disease

          -  Known diagnosis of HIV infection

          -  Pregnant or breast feeding females

        Please note: There are additional inclusion/exclusion criteria. The study center will
        determine if you meet all of the criteria. If you do not qualify for the trial, study
        personnel will explain the reasons. If you do qualify, study personnel will explain the
        trial in detail and answer any questions you may have.
Clinical trial NCT00722176 (phase 2, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: bl-1020, bl-1020 10-30 mg, risperidone
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female, 18-65 years of age at the time of entry into the BL-1020 IIb study

          2. Has provided informed consent to participate in the Extension Study

          3. Has completed 6 weeks of treatment and/or completed all efficacy assessments in Study
             BL-1020 IIb

          4. Females must have negative serum pregnancy test, or be post-menopausal, or if fecund,
             must practice established methods of birth control (oral contraceptive tablets,
             hormonal implant device, hormone patch, injectable contraceptive, intrauterine device
             [IUD]) for at least two months prior to screening

          5. Females must use an established method of birth control (as above) AND a barrier
             method (condom, diaphragm, contraceptive foam) while taking study medication

          6. Has a caregiver or an identified responsible person (e.g., family member, social
             worker, nurse) who will support him/her to ensure compliance with the treatment and
             outpatient visits

          7. Is willing to comply with not taking any prohibited medications during participation
             in the study

          8. Successful completion of End of Study assessments from BL-1020 IIb

        Exclusion Criteria:

          1. Is unwilling or unable to provide informed consent

          2. Is unwilling or unable, in the opinion of the Investigator, to comply with study
             instructions

          3. Has a medical condition that would put him/her at risk for continuing in the study

          4. Score > 9 on Modified InterSePT Scale for Suicidal Thinking (Modified ISST)

          5. Tested positive for drugs of abuse during the initial 6 weeks of treatment (Study
             BL-1020 IIb)

          6. Has been non-compliant with the study medication dosing and/or study procedures during
             the initial 6 weeks of treatment in Study BL-1020 IIb

          7. Is judged by the PI to be inappropriate for the study
Clinical trial NCT00288249 (phase 2, status: completed)
Conditions: breast neoplasms, breast cancer, metastatic
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: sagopilone (bay86-5302, zk 219477), sagopilone (bay86-5302, zk 219477), sagopilone (bay86-5302, zk 219477), sagopilone (bay86-5302, zk 219477)
SMILES: C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](CC=C)[C@H]1O)C1=CC=C2SC(C)=NC2=C1, C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](CC=C)[C@H]1O)C1=CC=C2SC(C)=NC2=C1, C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](CC=C)[C@H]1O)C1=CC=C2SC(C)=NC2=C1, C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](CC=C)[C@H]1O)C1=CC=C2SC(C)=NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Metastatic breast cancer

          -  No previous treatment with taxanes, and vinca alkaloids

          -  Use of highly effective birth control methods in females of child-bearing potential

        Exclusion Criteria:

          -  More than 2 previous chemotherapies

          -  Previous participation in another trial within the last 4 weeks

          -  Breast feeding

          -  Active infections
Clinical trial NCT00044993 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: docetaxel, doxorubicin hydrochloride
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed breast cancer

               -  Stage IIIA, IIIB (excluding inflammatory breast carcinoma), or IIIC OR

               -  Localized stage IV

          -  Measurable disease

          -  No metastases

          -  Hormone receptor status:

               -  Not specified

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Sex

          -  Male or female

        Menopausal status

          -  Not specified

        Performance status

          -  Karnofsky 70-100%

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Adequate bone marrow function

        Hepatic

          -  Adequate liver function

          -  Hepatitis B surface antigen negative

          -  Hepatitis C antibody negative

        Renal

          -  Adequate kidney function

        Cardiovascular

          -  Normal cardiac function by MUGA and/or echocardiogram

        Other

          -  No psychological, familial, sociological, or geographical conditions that would
             preclude study

          -  Not pregnant or nursing

          -  Fertile patients must use effective barrier method of contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No prior gene therapy using adenoviral vectors or p53 gene product

        Chemotherapy

          -  No prior chemotherapy for breast cancer

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified
Clinical trial NCT01023516 (phase 2, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: azd9668, placebo
SMILES: CN1N=CC=C1C1=C(C)N(C2=CC=CC(=C2)C(F)(F)F)C(=O)C(=C1)C(=O)NCC1=NC=C(C=C1)S(C)(=O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of COPD with symptoms over 1 year

          -  FEV1/FVC < 70% and FEV1 >= 30 and < 80 % of predicted post-bronchodilator

          -  Symptomatic COPD for a total of 7 days in the two weeks prior to randomisation

          -  At least 1 COPD exacerbation from 4 weeks to 12 months before the screening visit

        Exclusion Criteria:

          -  Past history or current evidence of clinically significant heart disease

          -  Current diagnosis of asthma

          -  Patients who require long term oxygen therapy

          -  Worsening of COPD requiring treatment with antibiotics, an increase in inhaled steroid
             dose and/or oral steroids within 4 weeks of study visit 1b
Clinical trial NCT00646659 (phase 2, status: terminated)
Conditions: head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: carboplatin, cisplatin, docetaxel, fluorouracil
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    recruitment was suspended prematurely for safety concerns and closed after idmc review
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed newly diagnosed squamous cell carcinoma of the head and neck

               -  Stage III or IV disease

               -  Unresectable disease

          -  Unidimensionally or bidimensionally measurable disease

          -  Skin and tumor material must be available for EGFR status and downstream signaling
             studies

          -  No nasopharyngeal, nasal, or paranasal cancer

          -  No distant metastases

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-1

          -  Absolute neutrophil count ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Bilirubin ≤ 1.5 times the upper limit of normal (ULN)

          -  Alkaline phosphatase and transaminases ≤ 2.5 times ULN

          -  Serum creatinine ≤ 120 μmol/L (1.36 mg/dL)

          -  Creatinine clearance ≥ 60 mL/min

          -  Normal cardiac function (i.e., LVEF ≥ 50%)

          -  Clinically satisfactory 12-lead ECG

          -  No serious cardiac illness or medical condition within the past 6 months

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No current malignancies at other sites with the exception of cone-biopsied carcinoma
             of the cervix and adequately treated basal or squamous cell skin carcinoma or other
             cancer from which the patient has been disease-free for at least the past five years

          -  No unstable systemic diseases

          -  No active uncontrolled infections

          -  No psychological, familial, sociological, or geographical condition that would
             preclude compliance with the study protocol and follow-up schedule

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior treatment for head and neck cancer

          -  No other concurrent anticancer therapy

          -  No other concurrent investigational agents
Clinical trial NCT01356368 (phase 2, status: terminated)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: cisplatin, gemzar, docetaxel, alimta
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Reason stopped: 
    slow accrual rate
  
Eligibility criteria:

        Inclusion Criteria:

          1. Microscopic diagnosis of NSCLC stages IIIB (with malignant pleural effusion) and IV

          2. Having adequate tissue sample to perform the markers testing

          3. Age ≥ 18 years

          4. No prior chemotherapy treatment for lung cancer (Surgery and radiotherapy are
             acceptable)

          5. No other concurrent cancer treatment

          6. Performance status of 0- 2 per ECOG scale (Appendix II)

          7. Adequate laboratory values as follows as follows:

             Absolute neutrophil count ≥ 1500/mm3 Platelet count ≥100, 000/ mm3 Total bilirubin ≤
             1.25X institutional upper normal level AST and ALT ≤ 3 X institutional upper normal
             level Serum creatinine ≤ 1.5 X institutional upper normal level

          8. Presence of measurable disease

        Exclusion Criteria:

          1. Prior systemic treatment for lung cancer

          2. History of hypersensitivity to drugs used

          3. Diagnosis of other malignancy in the last 5 years excluding curatively treated
             non-melanoma skin cancer and in-situ cervical cancer

          4. Medical illness that puts the patient at significant risk per investigator's
             discretion

          5. Uncontrolled CNS disease. Patients with CNS metastatic disease treated with
             radiotherapy or surgery will be eligible if the CNS disease is stable 4 weeks after
             the treatment initiation without increase dose of steroids

          6. Positive pregnancy test or refusal to use contraception during treatment. (Gynecology
             consultant for contraception)
Clinical trial NCT00319618 (phase 2, status: completed)
Conditions: metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: gefitinib, docetaxel
SMILES: COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed mammary carcinoma

        Exclusion Criteria:

          -  prior taxane chemotherapy for metastatic disease or prior treatment with tyrosine
             kinase inhibitors inhibiting the EGF receptor.

          -  Prior hormone treatment or one type of anthracycline based treatment regimen without
             taxane for metastatic disease is allowed prior to inclusion.

          -  If the patient has been treated in the adjuvant or neoadjuvant setting with taxanes,
             inclusion is allowed when the first cycle of trial medication is started 12 months
             after the last course of adjuvant treatment
Clinical trial NCT00634595 (phase 2, status: unknown status)
Conditions: head and neck squamous carcinoma, nasopharyngeal carcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: e10a, cisplatin, paclitaxel
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  histologically or cytologically confirmed recurrent or metastatic head and neck
             squamous carcinoma or nasopharyngeal carcinoma

          -  the tumor was amenable to direct injection and measurement ( > 2 cm)

          -  an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

          -  a life expectancy over three months

          -  the absence of serious medical or psychiatric disorders

          -  serum creatinine < 1.5 mg/dL; WBC count >3,000/mm3, platelet count > 80,000/mm3,
             hemoglobin > 8 g/dL; total bilirubin value < 1.5 times the upper limit of normal
             [ULN], ALT level < 2.5 times ULN, AST < 2.5 times ULN.

        Exclusion Criteria:

          -  pregnant or breast feeding

          -  a history of brain metastases or a primary brain tumor

          -  a history of hemorrhagic diathesis

          -  a history of corticosteroids or immunosuppressives use within four weeks of study
             entry

          -  a history of immune deficiency disorder or organ transplant

          -  has evidence of active adenovirus infection or uncontrolled infection

          -  received any chemotherapy or radiotherapy within four weeks of study entry
Clinical trial NCT00420420 (phase 2, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: mk0249, comparator: placebo (unspecified)
SMILES: CC1=NC2=CC=CC(=C2C(=O)N1C1=CC=C(OCCCN2CCCC2)C=C1)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or females

          -  Age at least 55 years or older

          -  Mild-to-moderate Alzheimer's Disease, with Mini Mental State Examination (MMSE)
             between 18 and 26, inclusive, Modified Hachinski Ischemic Scale (MHIS) score =/<4,
             Global CDR score of 1 or 2, and who have a reliable informant/caregiver to accompany
             patient to all clinic visits

          -  If using symptomatic Alzheimer's Disease treatments, patients must be on the
             medication for 3 months and on a STABLE DOSE for at least 2 months

        Exclusion Criteria:

          -  Patients cannot be living in a skilled nursing facility

          -  Patients cannot have poorly-controlled hypertension

          -  Patients cannot have the following conditions within 6 months of screening:
             significant cardiovascular disorders, active major depressive disorder,
             gastroesophageal reflux disease (GERD), or clinically significant sleep disorder

          -  Various concomitant therapy restrictions
Clinical trial NCT00508404 (phase 2, status: completed)
Conditions: metastatic colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: panitumumab, folfiri
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, FC1=CNC(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with histologically- or cytologically-confirmed metastatic adenocarcinoma of
             the colon and/or rectum.

          -  Measurable disease according to modified RECIST guidelines.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.

          -  Paraffin-embedded tissue or unstained tumour slides from primary or metastatic tumour
             available for central lab analysis.

          -  Adequate haematologic, renal, hepatic and metabolic function.

        Exclusion Criteria:

          -  Central nervous system metastases.

          -  Prior systemic therapy for the treatment of metastatic colorectal carcinoma with the
             exception of adjuvant fluoropyrimidine-based chemotherapy given at least six months
             prior to initiating study treatment.

          -  Prior anti-epidermal growth factor receptor (EGFr) antibody therapy (e.g. cetuximab)
             or treatment with small molecule EGFr tyrosine kinase inhibitors (e.g. erlotinib).

          -  Prior radiotherapy within 14 days prior to screening, and for which all signs of early
             radiological toxicity have not abated.

          -  Significant cardiovascular disease including unstable angina or myocardial infarction
             within six months before initiating study treatment or a history of ventricular
             arrhythmia.

          -  History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial
             pneumonitis or pulmonary fibrosis on baseline chest computed tomography (CT scan.

          -  Active inflammatory bowel disease or other bowel disease causing chronic diarrhoea
             (defined as > 4 loose stools per day).

          -  History of Gilbert's syndrome or dihydropyrimidine deficiency.

          -  Known positive test for human immunodeficiency virus infection, hepatitis C virus,
             chronic active hepatitis B infection.

          -  Any investigational agent within 30 days before initiation of study treatment.

          -  Must not have had a major surgical procedure within 28 days prior to initiation of
             study treatment.

          -  Subject who is pregnant or breast-feeding.

          -  Woman or man of childbearing potential not consenting to use adequate contraceptive
             precautions during the course of the study and for six months after the last study
             drug administration for women, and one month for men.

               -  Other protocol specified criteria and specific details may apply.
Clinical trial NCT01388491 (phase 2, status: completed)
Conditions: hemostasis, oral contraceptive
ICD codes: T38.4X1A, T38.4X1D, T38.4X1S, T38.4X2A, T38.4X2D, T38.4X2S, T38.4X3A
Drugs: desogestrel/ethinyl estradiol and ethinyl estradiol, desogestrel/ethinyl estradiol
SMILES: [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
Eligibility criteria:

        Inclusion Criteria:

          -  Premenopausal, non-pregnant, non-lactating women age 18-40 years old

          -  Body Mass Index (BMI) ≥18 kg/m² and <30 kg/m²

          -  Regular spontaneous menstrual cycle

          -  Others as dictated by FDA-approved protocol

        Exclusion Criteria:

          -  Any condition which contraindicates the use of combination oral contraceptives

          -  Any history of, or active, deep vein thrombosis, pulmonary embolism, or arterial
             thromboembolic disease within one year of screening

          -  Thrombophlebitis or thromboembolic disorders; known or suspected clotting disorders;
             thrombogenetic valvulopathies or rhythm disorders

          -  Others as dictated by FDA-approved protocol
Clinical trial NCT00652366 (phase 2, status: completed)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: erlotinib, escalating dose, erlotinib, standard dose, gemcitabine
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, >=18 years of age;

          -  histologically or cytologically confirmed pancreatic cancer with measurable or
             non-measurable metastatic disease;

          -  ECOG performance status of 0-1.

        Exclusion Criteria:

          -  local, or locally advanced, pancreatic cancer;

          -  prior systemic treatment for metastatic pancreatic cancer;

          -  <=6 months since last adjuvant chemotherapy;

          -  other malignancies within last 5 years, except for adequately treated cancer in situ
             of the cervix, or basal or squamous cell skin cancer.